Eric S. Daar

University of North Carolina at Chapel Hill — United States

Immunology and Microbiology · Life Sciences

65h-index18.5kcitations475works4.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV Research and Treatment(212), HIV/AIDS Research and Interventions(195), HIV/AIDS drug development and treatment(185), HIV-related health complications and treatments(97), SARS-CoV-2 and COVID-19 Research(56)

Publications460 total

Study protocol to evaluate an integrated intervention using a pill ingestible sensor system to trigger actions on multifaceted social and behavioral determinants of health among PLWH: an open-label, usual care-controlled, randomized trial
BMC Public Health·2025Open Access
Association of Intracellular Microstructural and Neuropsychological Changes in HIV: A Pilot Validation of Trace Diffusion-Weighted Magnetic Resonance Spectroscopic Imaging Using Radial Trajectories
UNC Libraries·2025Open Access
Association of Intracellular Microstructural and Neuropsychological Changes in HIV: A Pilot Validation of Trace Diffusion-Weighted Magnetic Resonance Spectroscopic Imaging Using Radial Trajectories
Metabolites·2025Open Access
Novel Criteria for Diagnosing Acute and Early Human Immunodeficiency Virus Infection in a Multinational Study of Early Antiretroviral Therapy Initiation
UNC Libraries·2025Open Access
Antiretroviral Therapy Intensification With Dolutegravir and/or Maraviroc Did Not Affect HIV-1 Cell-Associated DNA, RNA, and 2–LTR Circles Over 12 Weeks
Open Forum Infectious Diseases·2025Open Access
Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy
Open Forum Infectious Diseases·2025Open Access
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab
Clinical Infectious Diseases·2025· 1 citedOpen Access
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness
Clinical Infectious Diseases·2025· 3 citedOpen Access
SARS-CoV-2 monoclonal antibody treatment followed by vaccination shifts human memory B cell epitope recognition suggesting antibody feedback
UNC Libraries·2025Open Access
Safety and Efficacy of SAB-185 for Non-hospitalized Adults with COVID-19: A Randomized Clinical Trial
UNC Libraries·2025Open Access
Severe Acute Respiratory Syndrome Coronavirus 2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With Coronavirus Disease 2019
UNC Libraries·2025Open Access
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept
Clinical Infectious Diseases·2025Open Access
Association of Intracellular Microstructural and Neuro-Psychological Changes in HIV: A Pilot Validation of Trace Diffusion-Weighted Magnetic Resonance Spectroscopic Imaging Using Radial Trajectories
Preprints.org·2025Open Access
HepB-CpG Vaccine in People With HIV and Prior Nonresponse to HBV Vaccine
JAMA·2025· 2 citedOpen Access
Single-cell analyses identify monocyte gene expression profiles that influence HIV-1 reservoir size in acutely treated cohorts
Nature Communications·2025· 4 citedOpen Access
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab
Clinical Infectious Diseases·2025· 1 citedOpen Access
Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2
UNC Libraries·2025Open Access
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV
AIDS Research and Therapy·2025· 2 citedOpen Access
Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial
Contemporary Clinical Trials·2025
Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial
UNC Libraries·2025Open Access
page 1 of 23Next →

Frequent Co-authors

Susan J. Little(11), Paul E. Sax(8), Douglas D. Richman(6), David D. Ho(6), Peter Ruane(6), Ann C. Collier(5), Camlin Tierney(5), Nasreen C. Jahed(5), Edwin DeJesus(5), Elizabeth Connick(4), Tarsem Moudgil(4), Belinda Ha(4), Katie R. Mollan(4), Jean‐Michel Molina(4), Carlos del Rı́o(3), Roy M. Gulick(3), Joseph J. Eron(3), James F. Rooney(3), Grace A. McComsey(3), Douglas Kitch(3)